# The diagnostic yield of a structured comorbidity workup in a real-life outpatient population with obstructive sleep apnea: a cross-sectional study

**Authors:** Xiaolei Zhang, Huan Tang, Teng Han, Yiming Li, Linfan Su

PMC · DOI: 10.1080/07853890.2026.2622175 · Annals of Medicine · 2026-02-04

## TL;DR

A structured health check for people with sleep apnea finds many hidden health issues, leading to new treatments and referrals.

## Contribution

This study shows that a systematic comorbidity assessment in sleep apnea patients uncovers numerous actionable health conditions.

## Key findings

- A structured workup identified 3,200 new diagnoses in 1904 OSA patients.
- Common newly diagnosed conditions included dyslipidaemia, diabetes, hypertension, and heart issues.
- New findings led to treatment changes in 40% of patients and lifestyle advice in 85%.

## Abstract

Obstructive sleep apnea (OSA) is associated with multiple systemic complications. However, evidence-based recommendations for comorbidity screening remain sparse. This study aimed to evaluate whether a structured comorbidity workup could yield clinically meaningful diagnostic gains in OSA patients.

In this single-center cross-sectional observational study, patients diagnosed with OSA underwent a standardized comorbidity assessment including laboratory tests, electrocardiogram, echocardiography, abdominal ultrasound, ambulatory blood pressure monitoring, spirometry, and validated questionnaires.

A total of 1904 OSA patients were included. Before evaluation, patients had a median of two [IQR 1–2] known comorbidities. The structured workup identified 3,200 newly diagnosed conditions, with a median of two [IQR 1–2] new diagnoses per patient. The most frequent comorbidities were dyslipidaemia (55%), type 2 diabetes mellitus (32%), metabolic syndrome (31%), hypertension (30%), non-alcoholic fatty liver disease(29%), hyperuricemia (29%), significant coronary artery disease (15%), arrhythmia (16%), heart failure with preserved ejection fraction (13%), obesity hypoventilation syndrome (19%), chronic obstructive pulmonary disease (8%) , asthma (12%), gastro-oesophageal reflux disease (17%), anxiety or depression (17%), and thyroid dysfunction (6%). Older age, male sex and lower mean oxygen saturation were independently associated with a higher comorbidity burden. Newly identified conditions led to pharmacological treatment changes in 40%, specialist referral in 54%, and lifestyle interventions in 85% of cases.

A structured comorbidity workup in OSA patients reveals a high prevalence of previously unrecognized, clinically actionable conditions, particularly cardiometabolic disorders. Integrating systematic screening into routine OSA care may improve risk stratification, treatment optimization, and prevention of adverse outcomes (See Graphic Abstract).

## Linked entities

- **Diseases:** obstructive sleep apnea (MONDO:0007147), dyslipidaemia (MONDO:0002525), type 2 diabetes mellitus (MONDO:0005148), metabolic syndrome (MONDO:0000816), non-alcoholic fatty liver disease (MONDO:0013209), hyperuricemia (MONDO:0002144), coronary artery disease (MONDO:0005010), arrhythmia (MONDO:0007263), obesity hypoventilation syndrome (MONDO:0009763), chronic obstructive pulmonary disease (MONDO:0005002), asthma (MONDO:0004979)

## Full-text entities

- **Genes:** CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, SLC17A5 (solute carrier family 17 member 5) [NCBI Gene 26503] {aka AST, ISSD, NSD, SD, SIALIN, SIASD}, GPT (glutamic--pyruvic transaminase) [NCBI Gene 2875] {aka AAT1, ALT, ALT1, GPT1, SGPT}, NOXA1 (NADPH oxidase activator 1) [NCBI Gene 10811] {aka NY-CO-31, SDCCAG31, p51NOX}
- **Diseases:** hypercapnia (MESH:D006935), asthma (MESH:D001249), HFpEF (MESH:D054144), xerostomia (MESH:D014987), A/D (MESH:D014808), hypoxic (MESH:D002534), apnoea hypopnea (MESH:D012891), fatigue (MESH:D005221), T2DM (MESH:D003924), sleepiness (MESH:D000077260), OSA (MESH:D020181), central sleep apnea (MESH:D020182), apnea (MESH:D001049), HT (MESH:D006973), dyspnea (MESH:D004417), thyroid dysfunction (MESH:D013959), TD (MESH:D004409), dental erosion (MESH:D014077), hyperuricemia (MESH:D033461), neuropsychiatric (MESH:C000631768), hypothalamic-pituitary-adrenal (HPA) axis (MESH:D007029), ventricular tachyarrhythmias (MESH:D014693), obese (MESH:D009765), airway inflammation (MESH:D007249), metabolic (MESH:D008659), mood disorders (MESH:D019964), arrhythmia (MESH:D001145), OHS (MESH:D010845), Anxiety (MESH:D001007), cardiac impairment (MESH:D006331), dyslipidemia (MESH:D050171), chronic kidney disease (MESH:D051436), endothelial dysfunction (MESH:D014652), nocturnal (MESH:D009207), sleep fragmentation (MESH:D012892), HI (MESH:C538424), cardio (MESH:D059347), bradyarrhythmia (MESH:D001919), CAD (MESH:D003324), MS (MESH:D009103), comorbidity (MESH:D004194), nocturnal upper-airway obstruction (MESH:D000402), sleep (MESH:D012893), Generalised Anxiety Disorder (MESH:D001008), hypoxemia (MESH:D000860), COPD (MESH:D029424), respiratory complications (MESH:D012140), heart Failure (MESH:D006333), complications (MESH:D008107), cough (MESH:D003371), GERD (MESH:D005764), atherosclerotic (MESH:D050197), Depression (MESH:D003866), pulmonary hypertension (MESH:D006976), mouth breathing (MESH:D009058), atrial fibrillation (MESH:D001281), Cardiometabolic complications (MESH:D024821), NAFLD (MESH:D065626), disorder (MESH:D009358)
- **Chemicals:** uric acid (MESH:D014527), PAP (-), creatinine (MESH:D003404), glucose (MESH:D005947), triglycerides (MESH:D014280), carbon dioxide (MESH:D002245), cholesterol (MESH:D002784), oxygen (MESH:D010100)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12879501/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12879501/full.md

## References

40 references — full list in the complete paper: https://tomesphere.com/paper/PMC12879501/full.md

---
Source: https://tomesphere.com/paper/PMC12879501